| abstract |
The present invention relates to SNS-595 and provides a method for maximizing its therapeutic potential in human cancer therapy using its mechanism of action. The method includes determining an initial amount of at least one constituent protein of the DNA-PK pathway in a cancer cell to be treated and comparing the initial amount with a second amount. . [Selection figure] None |